Schrier Lectureship Looks at Changes in Treating Diabetic Kidney Disease

Full access
fig1

Thomas M. Coffman, MD, FASN

Citation: Kidney News 15, 10/11

Researcher Thomas M. Coffman, MD, FASN, will provide a clinical update on “Novel Therapies: On the Mechanisms of Action” in the Robert W. Schrier, MD, Endowed Lectureship on Thursday, November 2. The lecture will be presented during a session titled “Changing the Landscape of Diabetic Kidney Disease Treatment.”

Dr. Coffman is the dean of Duke-National University of Singapore (NUS) Medical School and the James R. Clapp Professor of Medicine at Duke University School of Medicine. Before moving to Singapore, Dr. Coffman held several leadership positions at Duke, including chief of the Division of Nephrology, vice chair of the Department of Medicine, and founding director of the Duke Cardiovascular Research Center. He was also the founding director of the Duke-NUS Cardiovascular and Metabolic Disorders signature research program.

Dr. Coffman's laboratory made seminal contributions to understanding diabetic nephropathy, hypertension, and the renin-angiotensin system. He has been a productive researcher, publishing more than 200 scientific papers. He is currently the lead investigator for DYNAMO (Diabetes Study in Nephropathy and Other Microvascular Complications), a large, collaborative study funded by the National Medical Research Council of Singapore.

Dr. Coffman also serves on the boards of directors of Singapore Health Services (the largest public hospital cluster in Singapore), the Singapore Eye Research Institute, the Singapore National Medical Research Council, and the King Faisal Specialist Hospital & Research Centre in Saudi Arabia.

An international leader in the field of nephrology, Dr. Coffman served ASN in many capacities—including as president—as well as treasurer of the International Society of Nephrology and a member of the nephrology subspecialty board of the American Board of Internal Medicine.

He has held a number of editorial positions, including associate editor of The Journal of Clinical Investigation. He currently serves on the editorial board of Cell Metabolism.

Among many honors, he received an award for excellence in hypertension research from the American Heart Association and a distinguished faculty award from the Duke Medical Alumni Association.

Dr. Coffman obtained his MD from The Ohio State University College of Medicine. He moved to Duke for his medicine residency and nephrology fellowship, joining the faculty in 1985 to pursue his career as a clinician and researcher.

Save